WASHINGTON — The Trump administration has launched TrumpRx.gov, a new federal website pitched as a direct shot at what it calls “price gouging” by major pharmaceutical companies — and a bid to bring U.S. prescription drug costs in line with prices paid in other developed countries.
The site markets “Most-Favored-Nation” (MFN) pricing, a policy framework rooted in a May 12, 2025 executive order directing federal agencies to pursue drug pricing that matches the lowest levels paid by comparable nations.
A new portal and a new political weapon against Big Pharma
TrumpRx.gov functions as a public-facing price and access portal, displaying “Lowest TrumpRx Price” figures next to “Original Price” listings for a range of high-demand brand-name drugs, including GLP-1 weight-loss and diabetes medications. On the site’s homepage, examples include Wegovy and Ozempic, with monthly prices shown far below the listed “original” amounts.
The website launched Feb. 5, 2026, and that 16 major drugmakers agreed to MFN-related deals tied to the administration’s pricing push.
Who it’s aimed at
According to Reuters, the program is focused on uninsured, cash-paying customers, with the site redirecting users to outside platforms to complete purchases.
Some TrumpRx pages also include eligibility language that excludes people enrolled in government-funded health programs, including Medicaid, Medicare (including Part D), VA, and TRICARE, depending on the product and program terms shown.
The administration’s argument: Americans shouldn’t subsidize the world
The underlying political case is straightforward: the White House argues Americans pay dramatically more for the same medicines, often produced in the same factories, while foreign health systems negotiate lower prices. The May 12, 2025 executive order spells out that premise and directs agencies to act accordingly.
What drugmakers are saying
At least one major manufacturer has publicly tied its participation to broader affordability messaging. Pfizer, for example, announced a TrumpRx-related cost-savings program covering more than 30 brands, calling it part of an agreement with the Trump administration to reduce costs for millions of Americans.
The fine print and the debate
Supporters frame TrumpRx as a consumer-first workaround to a system dominated by middlemen and opaque pricing. Critics, however, have questioned how much the website will materially change what most insured Americans pay and whether cash purchases through such portals would count toward deductibles and out-of-pocket maximums.
For now, TrumpRx.gov is being presented as both policy and populist message: a government-backed portal built to spotlight drug-price comparisons, and to put political heat on an industry the White House says has gotten away with charging Americans more than anyone else.
